Industry

Biogen to acquire Apellis for $5.6 billion

Healio Optometry2d ago1 min read

Editor’s note: This is a developing story. Please check back soon for updates.Under the terms of a definitive agreement, Biogen will acquire Apellis for $41 per share in cash, or approximately $5.6 billion, according to a press release from Biogen.The acquisition includes two FDA-approved commercialized medicines: Syfovre (pegcetacoplan injection) for geographic atrophy and Empaveli (pegcetacoplan) for complement 3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis and paroxysmal nocturnal hemoglobinuria. The combined net sales for the two treatments in 2025

Read full article on Healio Optometry

AI Summary

Quick Take

Biogen has reached a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, or $41 per share in cash. The deal secures Biogen two FDA-approved commercial medicines, most notably Syfovre (pegcetacoplan injection), the first approved treatment for geographic atrophy.

Why It Matters

This acquisition marks a significant move by Biogen to expand its footprint in the ophthalmic space by taking control of a first-in-class therapy for geographic atrophy. For the retina community, this transition of a major therapeutic asset from a smaller biotech to a large-cap pharmaceutical company could influence future market competition, patient access programs, and the scale of clinical education surrounding complement inhibition. It underscores the high commercial value and clinical priority currently placed on managing advanced dry age-related macular degeneration.

Key Details

Biogen will acquire all outstanding shares of Apellis for $41 per share in cash.
The total transaction value is estimated at approximately $5.6 billion.
The acquisition includes Syfovre (pegcetacoplan injection), an FDA-approved treatment for geographic atrophy.
The deal also includes Empaveli (pegcetacoplan), which is approved for paroxysmal nocturnal hemoglobinuria and rare kidney diseases including complement 3 glomerulopathy.
The move integrates Apellis's complement-based therapies into Biogen's broader portfolio.

Practice Implications

Clinicians currently prescribing Syfovre should stay alert for updates regarding potential changes to specialty pharmacy networks or patient support services during the transition. The backing of Biogen's commercial infrastructure may lead to increased resources for geographic atrophy screening and diagnosis in primary eye care and referral settings.

Who's Affected

Retina SpecialistsOphthalmologistsPractice OwnersGeriatric Optometrists

What's Next

As this is a developing story, further details regarding the expected closing date of the acquisition and the integration timeline for Apellis’s commercial operations are anticipated in future announcements.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.